Myriam Marianne Chaumeil1, Samuel Rose2, Subramanian Sukumar1, Hagit Dafni1, Manish Aghi2, Sabrina M. Ronen1
1Radiology, University of California San Francisco, San Francisco, CA, USA; 2Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
Macromolecular dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at 14.1Tesla was used to quantitatively measure the effect of antiangiogenic treatment with a Bevacizumab analogue in two glioblastoma (GBM) models: one responsive (U87) and one resistant (SF7796). Whereas no significant differences between GBMs were observed prior to treatment, antiangiogenic treatment induced a significant decrease in the mean values of permeability (PS, p=0.03) and blood volume fraction (fBV, p=0.001) in the responsive GBM model and no significant changes in the resistant one. Histogram analysis was also performed for both tumor types, allowing assessment of the heterogeneity of tumor response to treatment.